News|Articles|July 6, 2026

First Half 2026 Recap – Psychiatry

Fact checked by: Tim Smith

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

The first half of 2026 delivered significant regulatory and clinical momentum across psychiatry. The US Food & Drug Administration (FDA) expanded lumateperone (Caplyta) for schizophrenia relapse prevention, approved milsaperidone (Bysanti) for bipolar I disorder and schizophrenia, cleared ProlivRx as the first at-home neuromodulation device for major depressive disorder (MDD), and accepted centanafadine's NDA for priority review in ADHD.